TIRZ GLP-2Understand the science
How a pragmatic trial studies tirzepatide in everyday care
2 numbered sourcesSource years 2022, 2026
Peptides are short amino-acid chains whose links are peptide bonds. Some can mimic signals that help the body regulate nutrients and appetite. Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “GLP-2” in this catalog label does not identify a receptor it activates. In 2026, the SURMOUNT-REAL UK investigators published a plan to assess how offering tirzepatide would affect outcomes in a routine primary care setting. [1, 2]
The planned trial will randomize approximately 3,000 adults in Greater Manchester. Eligible participants have class I obesity and do not have diabetes. They will be assigned to standard care or to the offer of tirzepatide alongside standard care. Participants and care providers can know which group was assigned. The researchers will use electronic health records alongside other information to follow participants over five years. [1]
The main outcome is percentage change in body weight at two years. The investigators also plan to examine time to onset of type 2 diabetes by five years and measures such as healthcare use, quality of life and work-related outcomes. A trial that includes routine care can help researchers understand what happens when a treatment is offered in the system where people actually receive care. The comparison depends on the local setting and its definition of standard care. [1]
The 2026 paper describes a protocol. The planned number of participants and length of follow-up describe what the study intends to do. They are not results about weight, diabetes or healthcare use. The design identifies outcomes that differ from some of the shorter, more tightly controlled trials and makes those outcomes available for later comparison when findings are reported. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
